Biotec Pharmacon ASA, together with its subsidiaries, develops, manufactures, and markets immune modulating beta-glucans and recombinant enzymes in Norway.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Biotec Pharmacon's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: B4V's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: B4V exceeded the German Biotechs industry which returned 6.2% over the past year.
Return vs Market: B4V exceeded the German Market which returned 15% over the past year.
Price Volatility Vs. Market
How volatile is Biotec Pharmacon's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Biotec Pharmacon undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: B4V (€0.78) is trading above our estimate of fair value (€0.51)
Significantly Below Fair Value: B4V is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: B4V is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: B4V is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate B4V's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: B4V is overvalued based on its PB Ratio (8.4x) compared to the DE Biotechs industry average (3.5x).
How is Biotec Pharmacon forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotec Pharmacon has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Biotec Pharmacon's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Biotec Pharmacon competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Biotec Pharmacon performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: B4V is currently unprofitable.
Growing Profit Margin: B4V is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: B4V is unprofitable, but has reduced losses over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare B4V's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: B4V is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: B4V has a negative Return on Equity (-12.88%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Biotec Pharmacon's financial position?
Financial Position Analysis
Short Term Liabilities: B4V's short term assets (NOK52.5M) exceed its short term liabilities (NOK18.3M).
Long Term Liabilities: B4V's short term assets (NOK52.5M) exceed its long term liabilities (NOK12.7M).
Debt to Equity History and Analysis
Debt Level: B4V is debt free.
Reducing Debt: B4V has not had any debt for past 5 years.
Inventory Level: B4V has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if B4V's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable B4V has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: B4V is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 8.2% per year.
What is Biotec Pharmacon's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate B4V's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate B4V's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if B4V's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if B4V's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of B4V's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jethro Holter (47yo)
Mr. Jethro Holter has been interim CEO at Biotec Pharmacon ASA since October 23, 2019. Mr. Holter has been Managing Director of ArcticZymes AS at Biotec Pharmacon ASA since January 1, 2015. Mr. Holter join ...
CEO Compensation Analysis
Compensation vs Market: Jethro's total compensation ($USD164.88K) is below average for companies of similar size in the German market ($USD412.37K).
Compensation vs Earnings: Jethro's compensation has been consistent with company performance over the past year.
|Interim Chief Executive Officer||0.3yrs||kr1.53m||0.0012% NOK450.0|
|Chief Financial Officer||5.3yrs||kr1.31m||0.053% NOK20.2k|
|Director of IP & Business Development||15.4yrs||no data||no data|
Experienced Management: B4V's management team is considered experienced (3.8 years average tenure).
|Representative Director||2.8yrs||kr75.00k||0.033% NOK12.8k|
|Director||0.8yrs||no data||0.17% NOK63.7k|
|Employee Observer Director||0.8yrs||no data||0.042% NOK16.2k|
Experienced Board: B4V's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: B4V insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biotec Pharmacon ASA's company bio, employee growth, exchange listings and data sources
- Name: Biotec Pharmacon ASA
- Ticker: B4V
- Exchange: DB
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr385.711m
- Listing Market Cap: kr38.462m
- Shares outstanding: 48.33m
- Website: https://www.biotec.no
Number of Employees
- Biotec Pharmacon ASA
- Sykehusveien 23
- PO Box 6463
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIOTEC||OB (Oslo Bors)||Yes||Ordinary Shares||NO||NOK||Nov 2005|
|B4V||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Nov 2005|
|0DRV||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||NOK||Nov 2005|
|BIOTEO||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||NOK||Nov 2005|
Biotec Pharmacon ASA, together with its subsidiaries, develops, manufactures, and markets immune modulating beta-glucans and recombinant enzymes in Norway. It operates through Enzymes and Beta-Glucans segments. It offers Woulgan Gel, an active wound healing product containing soluble beta-glucan; M-Gard, an immunomodulator that enhances body’s defense mechanisms against pathogens, such as bacteria, virus, fungus, etc.; and M-Glucan, an immune-enhancing agent for various applications in the animal feed industry. The company also develops and markets recombinant enzymes that are derived from cold-water marine species for use in life science research and in the molecular diagnostics sector. Biotec Pharmacon ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/16 20:58|
|End of Day Share Price||2020/02/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.